No evidence of prolonged Hendra virus shedding by 2 patients, Australia by Taylor, Carmel et al.
No Evidence of 
Prolonged Hendra 
Virus Shedding 
by 2 Patients, 
Australia
Carmel Taylor, Elliott G. Playford, 
William J.H. McBride, Jamie McMahon, 
and David Warrilow
To better understand the natural history of Hendra virus 
infection and its tendency to relapse, 2 humans infected 
with this virus were monitored after acute infection. Virus 
was not detected in blood samples when patients were 
followed-up at 2 and 6 years. Thus, no evidence was found 
for prolonged virus shedding.
Most virus infections resolve after an acute phase. A small subset can cause persistent infection and result 
in continual shedding of virus, and others use a latency 
mechanism to evade the host immune response. Hendra and 
Nipah viruses (family Paramyxoviridae, genus Henipavirus) 
can cause respiratory disease and encephalitis in humans. 
Hendra virus infection is acquired by close contact with 
horses infected by spillover infection from fruit bats, which 
are the natural reservoir for these viruses (1).
In a small proportion of cases, relapse with encephalitis 
after a mild acute phase is a feature of henipavirus infection 
and is often fatal. For example, several cases of relapsing 
encephalitis caused by Nipah infection in humans have been 
reported (2–4), as well as 1 case caused by Hendra virus 
in a human (5,6). Whether virus shedding occurs after an 
acute infection of any severity is currently unclear. Because 
standard veterinary practice in Australia is to destroy 
animals that survive natural or experimental Hendra virus 
infection (7), long-term monitoring for virus shedding has 
not been possible.
To address the nature of viral persistence in cases 
of Hendra virus infection, virus shedding and serologic 
changes were monitored in 2 of 3 infected persons. In 
addition, multiple samples from 1 of these persons and from 
2 persons who died were compared to determine the most 
appropriate specimen type for detection by quantitative 
reverse transcription PCR (qRT-PCR).
The Study
Of 7 recognized humans infected with Hendra virus, 
3 survived. Of these 3 persons, clinical samples were 
available for 2 survivors. Patient 1 was a 25-year-old 
woman (veterinarian) in whom a self-limited infl uenza-like 
illness (ILI) developed in November 2004 (8). Patient 2 
was a 21-year-old woman (veterinary nurse) who showed 
development of an ILI that progressed to acute encephalitis 
in July 2008 (9). Although she survived, patient 2 showed 
persistent, postencephalitic, high-level cognitive defi cits. 
Currently, both patients do not show clinical evidence of 
relapse.
For this study, specimens were obtained from both 
patients at various times during acute-phase infection and 
during the convalescent phase. Blood was tested for IgG 
and IgM against Hendra virus. Nasopharyngeal aspirate 
(NPA), blood, urine, and cerebrospinal fl uid were tested 
for viral RNA by using qRT-PCR.
Both patients showed IgM and IgG responses to 
Hendra virus. For patient 1, no specimens were collected 
in the months after the acute phase and by 12 months, no 
IgM could be detected. However, IgG reactivity has been 
maintained for 6 years (Figure). Patient 2 has maintained IgM 
and IgG reactivity for >1.5 years after initial examination. 
The prolonged IgM response in patient 2 might have been 
caused by persistent infection or associated with more 
severe acute encephalitic manifestations. A prolonged IgM 
response has been observed in persons with West Nile virus 
meningitis, and encephalitis and may be a general aspect of 
central nervous system involvement (12,13).
Viral RNA was not detected in any specimen from 
patient 1 during the acute phase or at the 6-year follow-
up (Figure). Multiple samples from patient 2 were positive 
for virus during a 1-month period during the acute phase 
(Figure, Table). However, no samples showed positive 
results for Hendra virus RNA on subsequent follow-up. 
Thus, neither patient showed evidence of virus shedding 
after the acute phase (ILI or encephalitis).
To facilitate future PCR testing, we assessed various 
sample types for their suitability for detection of Hendra 
virus RNA during the acute phase of infection. In addition 
to patient 2, samples from 2 other case-patients with 
Hendra virus infection not described in this report (patients 
3 and 4) were tested. Patient 1 was not included because 
virus shedding was not detected at any time during her 
infection. Times chosen were from the earliest to the latest 
time point at which a positive result was obtained by qRT-
PCR (Table).
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Hendra virus RNA was detected in blood, NPA (or 
swab specimen), and urine, confi rming the suitability 
of these sample types. Frequency of detection varied for 
3 patients. None of the 3 sample types was consistently 
better than another, and all were suitable choices for 
diagnostic purposes. Hendra virus RNA was also detected 
in cerebrospinal fl uid, but there were too few samples to 
determine whether this material was a reliable sample type.
Conclusions
Serologic and PCR results were reported for the 2 
patients during the early phase of infection (8,9). Our 
study followed-up survivors of Hendra virus infection, 
and found no evidence for prolonged shedding of virus 
after acute infection. Because of the small total number of 
human cases and the high case-fatality rate, there are only 
3 known surviving patients with Hendra virus infection, 2 
whom were included in this study. Therefore, our results 
provide useful information for clinicians and public health 
offi cials for treating individual patients and minimizing the 
risk for transmission.
However, because of the small number of samples 
tested in this study, prolonged shedding after acute Hendra 
virus infection cannot be ruled out. In 1995, a patient 
who had an episode of aseptic meningitis after caring for 
2 Hendra virus–infected horses had a relapse 13 months 
after the initial episode (5). This patient also showed the 
potential for virus shedding during management of disease 
survivors. Thus, further monitoring of current and future 
survivors and experiments using a suitable animal model is 
required to answer this question.
The mechanism by which henipaviruses remain 
dormant is unknown. Virus has not been isolated from 
persons with relapse cases (2,5). This fi nding suggests that 
virus might persist in a noninfectious mutant form analogous 
to that which occurs with related measles virus during 
subacute sclerosing panencephalitis (14). In addition, the 
cellular reservoir for the virus and the mechanism by which 
it maintains latency are unknown.
It would be desirable to use PCR to test a variety 
of sample types for diagnosis of infection with Hendra 
virus. All sample types tested were suitable in terms of 
sensitivity. However, obtaining an NPA specimen during 
the acute phase of infection has a potential risk for aerosol 
contamination, and needle stick injury is a risk if a blood 
sample is obtained. Collection of a urine sample may be an 
acceptable risk without reducing the sensitivity of detection 
and risk to health care staff. This procedure should assist 
clinicians in management of henipavirus infections.
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Figure. Serologic and quantitative reverse transcription PCR (qRT-
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(11). The horizontal arrow indicates 3 samples stored at −80°C and 
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controls were included in all tests and showed expected results.
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